Chikungunya

Chikungunya is a viral disease due to chikungunya virus (CHIKV), which is described in the sources as a mosquito-borne alphavirus and a mosquito-transmitted pathogen ^[1][3]. The clinical syndrome is referred to as chikungunya fever or CHIKF, and the disease has been characterized as an emerging or re-emerging public-health concern ^[2][1][3]. The available sources do not provide a more detailed etiologic taxonomy beyond these descriptions ^[2][1][3].

The typical illness is febrile and is mainly characterized by severe joint pain and myalgia, with some sources also noting severe arthralgia and muscle pain ^[1][3]. Symptomatic illness is usually self-limited, but joint and muscle pain may persist for weeks or months, and one source states that arthralgia can persist for years ^[1][2]. Severe disease is reported in a minor proportion of infections, and neurologic complications such as encephalitis, meningitis, and Guillain-Barré syndrome have been described in outbreaks ^[1]. Rashes and prolonged disability are also noted in some patients, and death has been reported, although the cited sources do not quantify these outcomes ^[3][1].

Chikungunya virus is reported to be widespread across the tropics and to cause recurrent outbreaks, with major epidemic activity described over recent decades ^[2][3]. The sources specifically note outbreaks or affliction of populations in East and Central Africa, South America, Southeast Asia, Africa, Asia, the Indian Ocean region, the Caribbean, and the Americas ^[2][3]. Increasing geographic risk is linked in the sources to climate change, globalization of commerce and travel, virus evolution, and expansion of Aedes mosquito habitat ^[2][1][3]. The cited literature frames chikungunya as a substantial and growing public-health burden, but does not provide surveillance counts or incidence estimates in the supplied snippets ^[1][3].

Transmission is by mosquitoes, with Aedes aegypti and Aedes albopictus specifically identified in the sources ^[2][3]. One source describes CHIKV as mainly transmitted by Aedes aegypti in tropical and subtropical regions and notes potential for further spread related to adaptation to Aedes albopictus, which thrives in temperate regions ^[3]. The snippets do not provide additional exposure routes or non-vector transmission pathways ^[2][1][3].

The source material does not specify demographic or clinical high-risk groups for severe disease in a way that supports a firm list ^[2][1][3]. From the epidemiologic context provided, populations exposed to Aedes mosquitoes in tropical and subtropical regions, and communities affected by expanding mosquito habitat or outbreaks, are the groups most directly indicated by the sources as being at risk ^[2][3].

The cited sources emphasize surveillance and vector control as essential measures to suppress re-emergence and epidemics ^[2]. They also note that no specific antiviral treatment is available and that vaccines are still in development, indicating that preventive options remain limited in the referenced material ^[2][1]. The supplied sources do not describe specific personal protection, environmental control, or vaccine schedules ^[2][1].

In surveillance settings, chikungunya should be read as a vector-borne febrile illness with a strong tendency for outbreak activity in tropical and subtropical settings and increasing risk where Aedes mosquitoes expand or establish ^[2][1][3]. Monitoring is especially relevant for recurrent outbreaks, persistent post-acute morbidity, and the occasional appearance of neurologic or severe disease ^[2][1]. The supplied sources support close attention to travel, climate, and vector ecology as contextual drivers, but they do not provide case-definition details or reporting thresholds ^[2][1][3].

1. 1 de Lima Cavalcanti TYV et al. A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development. Viruses. 2022 May 5. PMID: 35632709. doi: 10.3390/v14050969. PubMed: https://pubmed.ncbi.nlm.nih.gov/35632709/
2. 2 Bartholomeeusen K et al. Chikungunya fever. Nat Rev Dis Primers. 2023 Apr 6. PMID: 37024497. doi: 10.1038/s41572-023-00429-2. PubMed: https://pubmed.ncbi.nlm.nih.gov/37024497/
3. 3 Burt FJ et al. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis. 2017 Apr. PMID: 28159534. doi: 10.1016/S1473-3099(16)30385-1. PubMed: https://pubmed.ncbi.nlm.nih.gov/28159534/
4. 4 Chikungunya Virus/Chikungunya-Related Arthritis. The APRN and PA’s Complete Guide to Prescribing Drug Therapy. 2019. doi: 10.1891/9780826179340.0066. DOI: https://doi.org/10.1891/9780826179340.0066
5. 5 Chikungunya. Red Book: 2024–2027 Report of the Committee on Infectious Diseases. 2024. doi: 10.1542/9781610027359-s3_003_004. DOI: https://doi.org/10.1542/9781610027359-s3_003_004
6. 6 Chikungunya. SpringerReference. None. doi: 10.1007/springerreference_85819. DOI: https://doi.org/10.1007/springerreference_85819

ICD-10

A92.0

ICD-11

1D46

Total cases

1.9M

Peak month

2024-03

Coverage

9 reporting countries · 2000-01-01 → 2026-06-20